First-line Durvalumab Improves Survival
Non-Small Cell Lung Cancer Patients See Improved Survival with Durvalumab | Moffitt
Daily Medication Pearl: Durvalumab (Imfinzi) for Non-Small Cell Lung Cancer
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial ...
Durvalumab (Imfinzi) - Uses, Dose, Side effects, MOA, Brands
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - Journal of Thoracic Oncology
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study - Clinical Lung
First-line Durvalumab Improves Survival
Imfinzi (durvalumab) Uses, Side Effects, Dosage +91 9310090915.
FDA places full, partial holds on durvalumab trials | MDedge Hematology and Oncology
Frontiers | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis - Practical Radiation Oncology
Durvalumab - Wikipedia
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the | DDDT
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer | Business Wire
Durvalumab in NSCLC: latest evidence and clinical potential | Semantic Scholar
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study - Journal of Thoracic Oncology
Durvalumab Combinations Push the Response Envelope in Unresectable NSCLC | MedPage Today
COAST Data Support Further Research of Immunotherapy Combinations - ILCN.org (ILCN/WCLC)
